Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.56 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | THPO | P40225 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9705702 | 0.79 | CYP1A2 (0.62) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL6438354 | 0.79 | ADORA1 (0.54) | CYP1A2CYP2D6MAPK1ADORA1ADORA2A | |
| SCHEMBL12498653 | 0.77 | CYP1A2 (0.78) | CYP1A2CYP2D6MAPK1ADORA1ADORA2A | |
| SCHEMBL22402771 | 0.77 | CYP1A2 (0.58) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL12410753 | 0.77 | PI4KA (0.60) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL5015543 | 0.76 | CYP1A2 (0.82) | CYP1A2CYP2D6MAPK1ADORA1ADORA2A | |
| SCHEMBL14924510 | 0.76 | CYP1A2 (0.82) | CYP1A2CYP2D6MAPK1ADORA1ADORA2A | |
| SCHEMBL13415584 | 0.76 | YTHDC1 (0.45) | CYP1A2CYP2D6MAPK1ADORA1ADORA2A | |
| SCHEMBL22399280 | 0.75 | CYP1A2 (0.76) | CYP1A2CYP2D6MAPK1ADORA1ADORA2A | |
| SCHEMBL22399527 | 0.75 | CYP1A2 (0.57) | CYP1A2CYP2D6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024119117-A1 | MODIFIED 5' CAP FOR MRNA AND METHODS OF USE THEREOF | PRIME MEDICINE, INC. (US) | 2024-06-06 | — | — | WO | disclosed |
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-02-29 | — | — | US | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-09-21 | — | — | US | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | ALNYLAM PHARMACEUTICALS, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-8492389-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2013-07-23 | — | — | US | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION (US) | 2012-05-31 | — | — | US | disclosed |
| US-8138195-B2 | Inhibitors of human phosphatidylinositol 3-kinase delta | ICOS CORPORATION (US) | 2012-03-20 | — | — | US | disclosed |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-07-01 | — | — | US | disclosed |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | ICOS CORPORATION | 2010-06-17 | — | — | US | disclosed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240066047-A1 | ANTIBODY-DRUG CONJUGATES COMPRISING A CYCLIC DINUCLEOTIDE | STING1, TLR9, CGAS | CYP1A2 4509/4885CYP2D6 3736/4885MAPK1 1398/4885 |
| US-20100152211-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CYP1A2 3429/4885CYP2D6 4308/4885MAPK1 154/4885 |
| US-20100168139-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CYP1A2 3429/4885CYP2D6 4308/4885MAPK1 154/4885 |
| US-20120135994-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CYP1A2 3429/4885CYP2D6 4308/4885MAPK1 154/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | CYP1A2 61/4885CYP2D6 23/4885MAPK1 4058/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | CYP1A2 4618/4885CYP2D6 4626/4885MAPK1 185/4885 |
| US-20120172591-A1 | INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PIK3CG | CYP1A2 3429/4885CYP2D6 4308/4885MAPK1 154/4885 |
| US-20230190785-A1 | COMPOSITIONS AND METHODS FOR SILENCING DNAJC15 GENE EXPRESSION | DNAJC13, DNAJC5, DNAJC7 | CYP1A2 4850/4885CYP2D6 4773/4885MAPK1 4193/4885 |
| US-20230256001-A1 | MODIFIED RNA AGENTS WITH REDUCED OFF-TARGET EFFECT | ADAR, SNRPE, ASGR1 | CYP1A2 4790/4885CYP2D6 4728/4885MAPK1 4752/4885 |
| US-20230295622-A1 | COMPOSITIONS AND METHODS FOR SILENCING MYOC EXPRESSION | MYOF, MYO3A, MYO3B | CYP1A2 4880/4885CYP2D6 4874/4885MAPK1 4202/4885 |
| US-20230340485-A1 | ANAPLASTIC LYMPHOMA KINASE (ALK) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALK, DGKG, EIF2AK2 | CYP1A2 4817/4885CYP2D6 4865/4885MAPK1 2634/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | CYP1A2 2684/4885CYP2D6 3588/4885MAPK1 4090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.